Header
Ihr Suchergebnis
Sie recherchieren derzeit unangemeldet.Melden Sie sich an (Login) um den vollen Funktionsumfang der Datenbank nutzen zu können.
Sie suchen in allen Bereichen nach dem Autor Heitmann M.
In der Rubrik Zeitschriften haben wir 2 Beiträge für Sie gefunden
-
MerkenUse of synthetic data in AI development
Rubrik: IT
(Treffer aus pharmind, Nr. 05, Seite 471 (2024))
Bunzel G | Bertram K | Erdmann N | Heitmann M | Jasper C
Use of synthetic data in AI development / Insights from a case study in Cryo-EM image analysis · Bunzel G1, Bertram K1, Erdmann N2, Heitmann M3, Jasper C4 · 1ATEM SD GmbH, Remscheid und Deloitte Wirtschaftsprüfungsgesellschaft GmbH, Düsseldorf und d-fine GmbH, Frankfurt und Charles River Microbial Solutions Germany GmbH, Kaarst
Unsupervised Machine Learning Synthetic Data Validation Adeno-Associated Viruses (AAV) Cryo-EM Personalized medicine and gene therapy are widely seen as mega trends in the pharmaceutical industry that will revolutionize the industry in the next few years [ 1 ]. One key factor for the success of gene therapy and personalized medicine, has been the use of adeno-associated viruses (AAV) DNA vectors. The AAV process has enabled the development of multiple high-value therapeutics with multi-million revenues per dose, as shown in tab. 1 [ 2 ]. Product Supplier Disease Area Licensed Price ($/dose) Lixturna Spark Therapeutics RPE65 retinal dystrophy 2017 0.85 million Zolgensma Novartis Spinal ...
-
MerkenGood Machine Learning Practices in GxP regulated areas
Rubrik: IT
(Treffer aus pharmind, Nr. 05, Seite 460 (2024))
Stueben J | Heitmann M | Baumann I
Good Machine Learning Practices in GxP regulated areas / An overview on regulatory and industry initiatives · Stueben J1, Heitmann M2, Baumann I3 · 1Boehringer Ingelheim International, Ingelheim, 2d-fine GmbH, Grünwald, 3Thescon GmbH, Coesfeld
Trustworthy AI Regulatory Initiatives Enabling Innovation European Commission FDA Collaborative Approach The first wholly AI-developed drug entered phase 1 trials in 2022 [ 1 ] - though AI is not only about the high-flying breakthroughs regarding new blockbusters or advances in the area of drug design for precision medicine. In fact, there are numerous use cases along the pharma value chain, supporting complex human assessment and decision making as well as control of automatized processes. To name a few examples: Effective knowledge management, mastering the increasingly overwhelming mass of scientific knowledge and literature Novel methodologies to assess clinical data, e.g. ...
